Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Sun Pharmaceutical has scheduled three analyst and investor meetings in June 2026. These meetings include participation in the BofA India, Morgan Stanley India Investment Forum, and Citi India Conferences, all held in Mumbai. No unpublished price sensitive information will be disclosed.
May 27 2026 16:01:53
Sun Pharmaceutical Industries Limited
Sun Pharma submitted an application to the stock exchanges for reclassification of shares. The request seeks to change the classification from 'Promoter Group' to 'Public' category, aligning with SEBI Listing Regulations.
May 26 2026 21:16:28
Sun Pharmaceutical Industries Limited
Sun Pharma will present pivotal long-term follow-up data for its drug UNLOXCYT (cosibelimab-ipdl) at the ASCO 2026 Annual Meeting on May 31. The clinical trial showed a 50% objective response rate, including 27% complete responses, and durable responses with a manageable safety profile in laCSCC.
May 26 2026 18:24:09
Sun Pharmaceutical Industries Ltd - 524715 - Additional Outcome Of The Board Meeting
Sun Pharma's Board of Directors approved the reclassification of certain promoter group individuals to the "Public" category. This reclassification is subject to approvals under SEBI Regulation 31A.
May 22 2026 18:17:30
Sun Pharmaceutical Industries Ltd - 524715 - Board Meeting Outcome for Recommendation Of Final Dividend
Sun Pharma's Board approved FY26 consolidated results: sales reached ₹58,220.1 cr (up 11.9% YoY) and net profit was ₹11,479.4 cr (up 5.0% YoY). The company also recommended a final dividend of ₹5 per share for FY26.
May 22 2026 15:02:33
Sun Pharmaceutical Industries Ltd - 524715 - Intimation For Receipt Of Requests For Reclassification Of Shareholder Category
Sun Pharma received requests from three Promoter Group members to reclassify 1.80% of their total shareholding to the 'Public' category. The Board of Directors will review these requests for approval.
May 14 2026 12:25:38
Sun Pharmaceutical Industries Ltd - 524715 - Board Meeting Intimation for Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended 31 March 2026 And Recommendation Of Final Dividend For FY 2025-26
Sun Pharmaceutical's board is scheduled to meet on May 22, 2026. The agenda includes considering and approving the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and recommending a final dividend for FY2025-26.
May 11 2026 19:13:43
Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Credit Rating
Sun Pharma's long-term bank facilities rating of 'Crisil AAA' has been placed on 'Rating Watch with Developing Implications' by CRISIL. This action follows the company's announcement of acquiring Organon & Co., with CRISIL to reassess post-acquisition. ICRA Limited reaffirmed its '[ICRA]AAA(Stable)' long-term rating.
May 07 2026 18:30:31
Sun Pharmaceutical Industries Limited
Sun Pharma held an investor call regarding its $11.75 billion enterprise value acquisition of Organon business. Management expects $350 million in synergies and the deal to be EPS accretive from day one, aiming to become a global pharma leader.
May 05 2026 23:16:53
Read More